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Abstract
Background: Obsessive-compulsive disorder is associated with a relevant impairment in social
and interpersonal functioning and severe disability. This seems to be particularly true for the poor
insight subtype, characterised by a lack of consciousness of illness and, consequently, compliance
with treatment. Poor responsiveness to serotonergic drugs in poor insight obsessive-compulsive
patients may also require an augmentation therapy with atypical antipsychotics.
Methods: We reviewed a case in which a patient with a long history of poor insight obsessive-
compulsive disorder was treated with a high dosage of serotonin reuptake inhibitors.
Results: The treatment resulted in a poor outcome. This patient was therefore augmentated with
aripiprazole.
Conclusion: Doctors should consider aripiprazole as a possible augmentation strategy for
serotonergic poor responder obsessive-compulsive patients, but further research on these
subjects is needed.
Background
Despite the fact atypical antipsychotics (AA) represent a
relatively novel pharmacological class, they are widely
prescribed by an increasing number of clinicians for het-
erogeneous conditions. Using AA augmentation therapy
for serotonin reuptake inhibitors (SRIs) refractory obses-
sive-compulsive disorder (OCD) with poor insight (PI) is
just one of such recently proposed clinical uses for this
class of drugs [1]. Although augmentation strategies for
OCD are quite often used by clinicians, literature data are
generally limited to some case reports or preliminary stud-
ies.
This lack of evidence seems even more relevant for specific
yet quite common OCD conditions, such as PI, reported
to be as prevalent as 15% to 36% all OCD cases [2], usu-
ally showing harder to treat features [3] and association
with a greater impairment in quality of life (QOL) [4].
Methods
The patient is a 34-year-old female with a severe PI-OCD,
first diagnosed 8 years ago. She was referred by her mother
to our outpatients department for worsening of OCD and
a progressive lack of insight started 3 years ago. She had
no other relevant medical or psychiatric comorbidities
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ders. For the first 4 years of treatment, she received parox-
etine 40 mg/day, showing poor response. When admitted
to the outpatients department, her obsessions were
mainly about being physically sick and bodily contami-
nated, with washing and cleaning compulsions. Addition-
ally, she showed intense fear of developing severe side
effects to the suggested therapy, resulting in belching com-
pulsions before taking medications.
Insight into her illness and therefore compliance to the
therapy was poor. In such scenarios, obtaining the
patient's compliance to medication was as important as it
was difficult to acheive. Because of her initial belching
compulsion, it required about 2 months to start a phar-
macological therapy. The patient was asked to answer the
Yale-Brown Obsessive-compulsive Scale (Y-BOCS) and
the Brown Assessment of Beliefs Scale (BABS) when a
maximum label dose therapy with sertraline at 200 mg/
day (100 mg twice a day) was started.
Results
The 2 submitted scales showed total scores of 50 and 23,
respectively, (with a score of 4 for the item 'conviction'
and 4 for the item 'insight' on the BABS); on the BABS
scale, 4 is the highest possible score and it indicates worse
sympthomatology [5,6].
A clinical follow-up was obtained after 1 month. The
patient was asked to answer the same rating scales again.
The new Y-BOCS total score was 47 while the BABS total
score was recorded at 22 ('conviction' and 'insight' items
were both scored as 4). Clinical improvement was poor
(the patient still showed avoidant behaviour and reluc-
tance to the pharmacotherapy). At this point, aripiprazole
10 mg/daily (in the morning) was introduced as augmen-
tation strategy.
The second clinical follow-up was obtained 1 month later.
The Y-BOCS total score was now 40 and the BABS total
score was 19 (the 'conviction' and the 'insight' items were
scored as 3). At this point the patient showed mild clinical
improvement (same obsessions and compulsions were
still present, but less intrusive).
At this point, an alternative therapy with clomipramine
was also considered, but it was discarded because of a pos-
itive anamnesis for Sjogren syndrome, with xerostomia as
a possible exacerbating factor due to the anticholinergic
side effect of the considered drug.
The last clinical follow-up was obtained at the 120th day
from the beginning of the therapy. The Y-BOCS total score
was 32 and the BABS total score was 17 (the 'conviction'
and the 'insight' items scored 4 – one more than previ-
ously). At this point the patient showed a further mild
clinical improvement, requiring a longer follow-up.
Conclusion
Obsessions and delusions have been traditionally viewed
as dichotomous phenomena, with obsessions been
defined as 'intrusive, ego-dystonic thoughts with the
patient maintaining insight'.
By contrast, delusions have been defined as false beliefs
held firmly by the patient without insight into the irra-
tionality of the belief. However, obsessions and delusions
may be better conceptualised as existing on a continuum
of insight that ranges from good insight (overvalued idea-
tion, as in typical OCD) to poor insight/no insight (delu-
sional thinking, as in severe PI-OCD). Such a continuum
of insight may be present among a variety of psychiatric
disorders, such as OCD (including the PI subtype), dys-
morphic disorder, hypochondriasis, eating disorders and
psychotic disorders, such as schizophrenia and delusional
disorder [6].
Psychiatric disorders sharing the 'psychotic' feature have
been traditionally effectively treated using typical antipsy-
chotics (AT). More recently clinicians switched to AA from
AT to avoid their side effects (such as tardive dyskinesia)
to treat schizophrenia as well as other 'psychotic' condi-
tions [7]. Among 'psychotic-like' disorders, PI-OCD is one
of the less investigated, mainly due to a relatively low
prevalence and difficulty in detection of clinical features.
Therefore we have a lack of available data in the literature
for AA, especially for the most recently introduced drugs
such as aripiprazole.
Nevertheless, available studies have demonstrated that
selective SRI (SSRI) augmentation with AAs should be
considered as a strategy for OCD patients who fail to show
a treatment response after an 'adequate treatment', as
defined by APA guidelines [8]. Additionally, in this partic-
ular patient, a history of poor clinical response to ade-
quate SSRI therapy, as well as a persistent lack of insight
and compliance, suggested treatment augmentation with
AA.
The choice of aripiprazole from different AA agents was
also suggested by its hypothesised mechanism of action.
Aripiprazole is chemically different from other AA agents,
acting as a weak stimulator of dopamine D2 receptors (the
drug is a so-called partial agonist) with an antagonistic
(inhibitory) or agonist (stimulating) activity, depending
on the sensibility of the receptors and the availability of
dopamine (DA). The D2 receptors are present both presy-
naptically (as autoinhibitory targets) and postsynaptically
(as stimulating-heteroreceptors).Page 2 of 3
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Dose-dependent effects are exerted mainly on the presyn-
aptic D2 receptors with low concentrations of the antipsy-
chotic agent, while higher dosages have the opposite effect
(acting on the postsynaptic target) [9].
Aripiprazole exerts similar partial agonist effects on serot-
onin 1A receptors (5-HT1A), differently to the mechanism
of other AA agents. The whole AA class share the '5-HT2A
> D2' blocking mechanism [10]. Furthermore, some
authors, after reviewing published and unpublished data,
suggested that aripiprazole would not affect serotonin (5-
HT) receptors at therapeutic doses [11].
In vivo studies in rats report a reduced 5-HT and an
increased DA output in the medial prefrontal cortex
(mPFC) and dorsal raphe nucleus compared to haloperi-
dol, through the activation of 5-HT1A receptors [12]. This
specific pharmacodynamic properties suggest that arip-
iprazole is a 'new generation' AA. Consequently, aripipra-
zole augmentation should lead to a greater clinical
improvement of PI-OCD patients compared to patients
on SSRIs. Furthermore, evidence of a DA involvement in
OCD is confirmed both by animal and clinical studies
[13].
In summary, in view of the clinical and pharmacody-
namic aspects, the patient's mild clinical improvement
appeared significant compared to the clinical response
previously obtained with just SSRIs. We also hypothesised
that a longer follow-up with SSRI augmentation with arip-
iprazole would produce a further improvement of the
OCD sympthomatology.
Finally, even if caution is suggested before switching to a
relatively novel treatment, we hypothesise that aripipra-
zole is a useful adjunctive drug in the therapy of severe PI-
OCD patients. Because of paucity of data on the use of
aripiprazole in PI-OCD patients, our hypothesis should
be further investigated in larger patients sample with the
use of systematic investigations including randomised
clinical trials (RCTs).
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